Table 3.
Results of mSFRP2, mSDC2 and SpecColon test in detecting CRC among different ages, genders, stage, tumor locations, tumor sides and tumor sizes by cut-off-2 in the training cohort
| mSFRP2 (%) | p-value | mSDC2 (%) | p-value | SpecColon (%) | p-value | |
|---|---|---|---|---|---|---|
| Age | ||||||
| <60 (n=52) | 65.4 (34/52) | 0.206 | 76.9 (40/52) | 0.625 | 82.7 (43/52) | 0.770 |
| ≥60 (n=59) | 76.3 (45/59) | 72.9 (43/59) | 84.8 (50/59) | |||
| Gender | ||||||
| Male (n=63) | 77.8 (49/63) | 0.078 | 82.5 (52/63) | 0.031 | 87.3 (55/63) | 0.249 |
| Female (n=48) | 62.5 (30/48) | 64.6 (31/48) | 79.2 (38/48) | |||
| Stage | ||||||
| 0-II (n=55) | 78.2 (43/55) | 0.128 | 78.2 (43/55) | 0.494 | 89.1 (49/55) | 0.151 |
| III-IV (n=47) | 61.7 (29/47) | 72.3 (34/47) | 78.7 (37/47) | |||
| Location | ||||||
| Proximal (n=56) | 78.6 (44/56) | 0.052 | 73.2 (41/56) | 0.788 | 83.9 (47/56) | 0.755 |
| Distal (n=49) | 61.2 (30/49) | 75.5 (37/49) | 81.6 (40/49) | |||
| N/A (n=6) | 83.3 (5/6) | 83.3 (5/6) | 100.0 (6/6) | |||
| Side | ||||||
| Left (n=86) | 76.6 (66/86) | 0.001 | 77.9 (67/86) | 0.178 | 86.1 (74/86) | 0.065 |
| Right (n=19) | 42.1 (8/19) | 63.2 (12/19) | 68.4 (13/19) | |||
| N/A (n=7) | 85.7 (6/7) | 71.4 (5/7) | 100.0 (7/7) | |||
| Size | ||||||
| <3 cm (n=17) | 70.6 (12/17) | 0.710a | 58.8 (10/17) | 0.037a | 82.4 (14/17) | 0.640a |
| 3-6 cm (n=68) | 75.0 (51/68) | 0.700b | 82.4 (56/68) | 0.203b | 86.8 (59/68) | 0.527b |
| >6 cm (n=11) | 63.6 (7/11) | 0.429c | 81.8 (9/11) | 0.966c | 90.9 (10/11) | 0.701c |
| N/A (n=15) | 60.0 (9/15) | 53.3 (8/15) | 66.7 (10/15) |
N/A, not applicable. a, p-value between <3 cm and 3-6 cm; b, p-value between <3 cm and >6 cm; c, p-value between 3-6 cm and >6 cm.